Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02977299 · ClinicalTrials.gov registry record · Phase 4
Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 278
- Enrollment target
NCT02977299: Completed Phase 4 study, sponsored by Massachusetts General Hospital.
NCT02977299 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 278 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02977299, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 278 participants
- Enrollment target
Study Summary
This is a multi-site, randomized, open-label, effectiveness trial comparing three treatment arms for Major Depressive Disorder (MDD) patients with TRD who are currently on ongoing, stable and adequate antidepressant therapy (ADT). Adequate ADT is defined as a therapeutically sufficient dose for a sufficient treatment period, which would be expected to be effective as listed in the MGH Antidepressant Treatment Response Questionnaire (ATRQ). Patients will be randomized in a 1:1:1 fashion to one of three open-label treatment arms: a) aripiprazole augmentation, b) rTMS augmentation, and c) switching to venlafaxine XR or Duloxetine.
Interventions
- DEVICE Repetitive transcranial magnetic stimulation (rTMS)
- DRUG Aripiprazole
- DRUG Venlafaxine XR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 278 participants |
| Start Date | 2017-07-13 |
| Est. Completion | 2022-04-24 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02977299
The ClinicalTrials.gov registry entry for NCT02977299 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 278 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Repetitive transcranial magnetic stimulation (rTMS) is the first listed.
NCT02977299 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02977299 about?
NCT02977299 is a clinical study titled "Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD". This is a multi-site, randomized, open-label, effectiveness trial comparing three treatment arms for Major Depressive Disorder (MDD) patients with TRD who are currently on ongoing, stable and adequate antidepressant therapy (ADT). Adequate ADT is defined as a therapeutically sufficient dose for a su...
What is the current status of trial NCT02977299?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 278 participants. The study started on 2017-07-13. Estimated completion is 2022-04-24.
What interventions are being tested in trial NCT02977299?
The interventions under investigation include: Repetitive transcranial magnetic stimulation (rTMS) (DEVICE), Aripiprazole (DRUG), Venlafaxine XR (DRUG).
Who is sponsoring clinical trial NCT02977299?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.